Like you pointed out, Divi’s as a case of contract manufacturing stands to gain but we also think that the largecaps -- Sun, Dr Reddy, Lupin -- have a very strong pipeline and in the next three-four quarters the cash enhancement should be on the cards.
For More Details Visit-
via There could be a 20% upside in pharma largecaps in next 9 to 12 months: Dipan Mehta
No comments:
Post a Comment